TO: Durable Medical Equipment Providers

FROM: Susan J. Tucker, Executive Director
       Office of Health Services

RE: Coverage of Continuous Glucose Monitoring Systems

NOTE: Please ensure that appropriate staff members in your organization are informed of the contents of this memorandum.

Effective October 1, 2016, Maryland Medicaid will begin covering continuous glucose monitoring (CGM) systems when medically necessary for Medical Assistance participants.

The product is a glucose monitoring device indicated for tracking patterns and detecting trends in persons with diabetes. The system includes several components: a sensor, transmitter, and receiver. The sensor is a small wire that is inserted under the skin of the abdomen and measures interstitial glucose values. These values are sent through the transmitter to the receiver where they are displayed for the user. The system is indicated as an adjunct to complement, not replace, information obtained from standard home blood glucose monitoring devices. The system aids in the detection of episodes of hyperglycemia and hypoglycemia and can help inform short-term and long-term therapy adjustments.

As mentioned in Medical Supply and Equipment Transmittal No. 69 / Oxygen Transmittal No. 30, dated August 12, 2016, Telligen, the Department’s utilization control agent, will be responsible for preauthorizing certain durable medical equipment (DME) requests, which includes CGM systems. Instructions for submitting requests to Telligen can be found at http://www.telligenmd.qualitrac.com/education-training. The current prepayment form, CGM certificate of medical necessity (CMN), and fee schedule can be downloaded at https://mmcep.dhmh.maryland.gov/communitysupport/Pages/Home.aspx.

Any questions regarding this transmittal should be directed to a DME Staff Specialist at 410-767-7238 or dhmh.dcss@maryland.gov.

Attachment (1)

cc: Oxygen and Respiratory Providers
    Utilization Control Agent, Telligen